These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16678056)

  • 1. Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer.
    Bradford TJ; Wang X; Chinnaiyan AM
    Urol Oncol; 2006; 24(3):237-42. PubMed ID: 16678056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum-autoantibodies for discovery of prostate cancer specific biomarkers.
    Massoner P; Lueking A; Goehler H; Höpfner A; Kowald A; Kugler KG; Amersdorfer P; Horninger W; Bartsch G; Schulz-Knappe P; Klocker H
    Prostate; 2012 Mar; 72(4):427-36. PubMed ID: 22012634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibody profiles as biomarkers of breast cancer.
    Tabernero MD; Lv LL; Anderson KS
    Cancer Biomark; 2010; 6(5-6):247-56. PubMed ID: 20938085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies in prostate cancer.
    Rocco B; Djavan B; de Cobelli O
    N Engl J Med; 2005 Dec; 353(26):2815-7; author reply 2815-7. PubMed ID: 16382547
    [No Abstract]   [Full Text] [Related]  

  • 5. Serum markers for prostate cancer: a rational approach to the literature.
    Steuber T; O'Brien MF; Lilja H
    Eur Urol; 2008 Jul; 54(1):31-40. PubMed ID: 18243505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard treatments induce antigen-specific immune responses in prostate cancer.
    Nesslinger NJ; Sahota RA; Stone B; Johnson K; Chima N; King C; Rasmussen D; Bishop D; Rennie PS; Gleave M; Blood P; Pai H; Ludgate C; Nelson BH
    Clin Cancer Res; 2007 Mar; 13(5):1493-502. PubMed ID: 17332294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens.
    Zhang JY; Casiano CA; Peng XX; Koziol JA; Chan EK; Tan EM
    Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):136-43. PubMed ID: 12582023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood biomarkers for prostate cancer detection and prognosis.
    Shariat SF; Karam JA; Roehrborn CG
    Future Oncol; 2007 Aug; 3(4):449-61. PubMed ID: 17661720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoantibodies in prostate cancer.
    Tan EM; Koziol JA
    N Engl J Med; 2005 Dec; 353(26):2815-7; author reply 2815-7. PubMed ID: 16382071
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of a "reverse capture" autoantibody microarray for studies of antigen-autoantibody profiling.
    Qin S; Qiu W; Ehrlich JR; Ferdinand AS; Richie JP; O'leary MP; Lee ML; Liu BC
    Proteomics; 2006 May; 6(10):3199-209. PubMed ID: 16596707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies in prostate cancer.
    Thorat MA; Badwe RA
    N Engl J Med; 2005 Dec; 353(26):2815-7; author reply 2815-7. PubMed ID: 16382548
    [No Abstract]   [Full Text] [Related]  

  • 12. New circulating biomarkers for prostate cancer.
    Bensalah K; Lotan Y; Karam JA; Shariat SF
    Prostate Cancer Prostatic Dis; 2008; 11(2):112-20. PubMed ID: 17998918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibodies in prostate cancer.
    Kida Y
    N Engl J Med; 2005 Dec; 353(26):2815-7; author reply 2815-7. PubMed ID: 16382546
    [No Abstract]   [Full Text] [Related]  

  • 14. Profiling tumor-associated autoantibodies for the detection of colon cancer.
    Ran Y; Hu H; Zhou Z; Yu L; Sun L; Pan J; Liu J; Yang Z
    Clin Cancer Res; 2008 May; 14(9):2696-700. PubMed ID: 18451234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen.
    Paul B; Dhir R; Landsittel D; Hitchens MR; Getzenberg RH
    Cancer Res; 2005 May; 65(10):4097-100. PubMed ID: 15899799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibody signatures in prostate cancer.
    Wang X; Yu J; Sreekumar A; Varambally S; Shen R; Giacherio D; Mehra R; Montie JE; Pienta KJ; Sanda MG; Kantoff PW; Rubin MA; Wei JT; Ghosh D; Chinnaiyan AM
    N Engl J Med; 2005 Sep; 353(12):1224-35. PubMed ID: 16177248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers for prostate cancer detection.
    Parekh DJ; Ankerst DP; Troyer D; Srivastava S; Thompson IM
    J Urol; 2007 Dec; 178(6):2252-9. PubMed ID: 17936845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
    D'Amico A
    BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.